FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.
Myriad Genetics secures FDA approval for MyChoice CDx in ovarian cancer. Discover how HRD testing could reshape PARP inhibitor treatment decisions.
Guardant Health and Merck announce global CDx collaboration using Infinity Smart liquid biopsy platform. Find out what this means for oncology drug development.
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Wenzhou KanryBio Biotechnology Co., Ltd. have entered into a strategic collaboration focused on co-developing high-value reagents and products for biomarker assay kits. Announced on December 10, 2025, this partnership aims to combine Sanyou Biopharmaceuticals’ global leadership in AI-driven molecular discovery with KanryBio Biotechnology’s capabilities in kit product development and […]